Bordetella bronchiseptica cDNA and Antigen

Bordetella bronchiseptica is a Gram-negative bacterium that is associated with a range of respiratory infections in a variety of animals, including dogs, cats, pigs, and rabbits. This bacterium possesses several virulence factors that are essential for the establishment and progression of infection. Here, we will discuss three of the most important virulence factors of Bordetella bronchiseptica: surface antigens, the 60 kDa chaperonin Cpn60, and Bordetella bronchiseptica A.

Surface Antigens:

Bordetella bronchiseptica surface antigens are proteins that are exposed on the surface of the bacterium and play a crucial role in the pathogenesis of respiratory infections. They are responsible for the adhesion of the bacterium to host cells, allowing it to colonize and establish infection. Some of the key surface antigens of Bordetella bronchiseptica include filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae. These antigens are highly immunogenic, and antibodies against them can confer protection against infection.

60 kDa Chaperonin Cpn60:

The 60 kDa chaperonin Cpn60 is a highly conserved protein that is found in a variety of bacteria, including Bordetella bronchiseptica. It is involved in protein folding and plays a critical role in the survival and growth of the bacterium. Studies have shown that the 60 kDa chaperonin Cpn60 of Bordetella bronchiseptica is essential for the bacterium to establish respiratory infection in animals. It is thought to be involved in the colonization of the respiratory tract and the evasion of host immune responses.

Bordetella bronchiseptica A:

Bordetella bronchiseptica A is a surface protein that is unique to Bordetella bronchiseptica. It is a highly conserved protein that is involved in the adhesion of the bacterium to host cells. Studies have shown that Bordetella bronchiseptica A is an essential virulence factor that is required for the bacterium to colonize the respiratory tract and cause disease. Antibodies against Bordetella bronchiseptica A have been shown to provide protection against infection, making it a potential target for vaccine development.

In conclusion, Bordetella bronchiseptica possesses several virulence factors that are essential for the establishment and progression of respiratory infections. Understanding these virulence factors is essential for the development of effective treatments and vaccines to combat this bacterium.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA (complementary DNA) and recombinant antigens of Bordetella bronchiseptica have various applications in the fields of molecular biology and infectious disease, including:

Gene expression analysis: The cDNA can be used as a template to synthesize complementary RNA (cRNA) which can then be used for microarray or RNA sequencing (RNA-seq) analysis to study gene expression patterns in the bacterium under different conditions.

Antimicrobial resistance studies: The cDNA can be used to study the mechanisms of antibiotic resistance in Bordetella bronchiseptica, including the identification of genes involved in resistance and the evaluation of the expression of these genes.

Vaccine development: The recombinant antigens of Bordetella bronchiseptica can be used to develop subunit vaccines against the bacterium. These antigens can stimulate the immune system to mount a response against the pathogen.

Diagnostics: The cDNA can be used to develop real-time PCR (polymerase chain reaction) assays for the rapid and sensitive detection of Bordetella bronchiseptica in clinical specimens, such as nasal swabs, bronchoalveolar lavage fluids, and tracheal aspirates.

Serological assays: The recombinant antigens of Bordetella bronchiseptica can be used to develop serological assays, such as ELISA (enzyme-linked immunosorbent assay), to detect the presence of antibodies against the bacterium in animal serum. These assays can be used for the diagnosis of Bordetella bronchiseptica infections.